Blai Coll
Fortuna: 600 072 $ al 31/05/2026
Fortuna: 600 072 $ al 31/05/2026
Blai Coll currently works at Structure Therapeutics, Inc., as Chief Medical Officer from 2024.
Dr. Coll also formerly worked at AbbVie, Inc., as Medical Director.
Dr. Coll received his doctorate degree from Autonomous University of Barcelona and doctorate degree from Universitat Rovira i Virgili.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/04/2026 | 45.765 ( 0,03 % ) | 600 072 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Director Técnico/Científico/I+D | 18/09/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| ABBVIE INC. | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 4 |
|---|---|
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
Autonomous University of Barcelona
Autonomous University of Barcelona Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universitat Rovira i Virgili
Universitat Rovira i Virgili Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Structure Therapeutics, Inc.
Structure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops molecule therapeutics to treat chronic diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.